FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - July 4, 2025 602 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Aspirin Being Investigated as Possible Treatment for Triple Negative Breast Cancer August 21, 2021 Effects of Patient Navigation, Lower-Cost Drug Alternatives on the Cost of... September 26, 2022 Increased Risk of Cancer in Early Life Among Individuals with Autism... April 28, 2022 Asciminib Shows Superior Efficacy Over Investigator-Selected TKIs and Imatinib in Patients... June 17, 2024 Load more HOT NEWS “No Person With Cancer or Survivor Should Ever Feel Alone”: A... Hospital Mistakenly Gave Woman a Mastectomy, Then Postponed Her Reconstruction for... Woman Who Lost Husband to Male Breast Cancer Goes on Road... EMA Recommends Granting a Marketing Authorisation for Generic Nilotinib
